Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Net Income towards Common Stockholders: 2017-2025

Historic Net Income towards Common Stockholders for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to -$15.3 million.

  • Aclaris Therapeutics' Net Income towards Common Stockholders fell 80.78% to -$15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$145.2 million, marking a year-over-year decrease of 279.49%. This contributed to the annual value of -$132.1 million for FY2024, which is 49.26% down from last year.
  • Per Aclaris Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$15.3 million for Q3 2025, which was up 6.47% from -$16.4 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Net Income towards Common Stockholders ranged from a high of -$1.9 million in Q4 2023 and a low of -$97.6 million during Q4 2024.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$16.4 million (2025), whereas its average is -$25.0 million.
  • As far as peak fluctuations go, Aclaris Therapeutics' Net Income towards Common Stockholders plummeted by 66,588.89% in 2021, and later surged by 93.61% in 2023.
  • Over the past 5 years, Aclaris Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$22.9 million in 2021, then fell by 27.02% to -$29.1 million in 2022, then surged by 93.61% to -$1.9 million in 2023, then tumbled by 5,151.45% to -$97.6 million in 2024, then slumped by 80.78% to -$15.3 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$15.3 million for Q3 2025, versus -$16.4 million for Q2 2025 and -$15.9 million for Q1 2025.